Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $43.80.
Several analysts have recently weighed in on INO shares. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Oppenheimer cut their target price on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $15.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, July 15th.
Institutional Trading of Inovio Pharmaceuticals
Inovio Pharmaceuticals Price Performance
Shares of INO opened at $5.70 on Wednesday. Inovio Pharmaceuticals has a 1-year low of $3.89 and a 1-year high of $14.75. The stock has a market cap of $147.69 million, a PE ratio of -1.54 and a beta of 0.82. The firm has a 50-day simple moving average of $6.43 and a two-hundred day simple moving average of $8.83.
Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. During the same period last year, the firm posted ($1.56) earnings per share. As a group, sell-side analysts expect that Inovio Pharmaceuticals will post -4.64 earnings per share for the current fiscal year.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Further Reading
- Five stocks we like better than Inovio Pharmaceuticals
- Basic Materials Stocks Investing
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Following Congress Stock Trades
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.